By physician referral or invitation only

ACCL1931 - Levocarnitine as Prophylaxis for Hepatotoxicity in AYA (15-39.9) with de novo ALL/Lly/MPAL

To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia (>3 mg/dL) during ALL induction therapy in adolescents and young adults (AYAs, age 15-39 years).

Age & Gender

15 years ~ 39.9 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Thomas Alexander
Pediatrics - Hematology/Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Pediatric Cancers, Leukemia)
Kidneys and Liver

IRB Number

23-2296

ClinicalTrials.gov

NCT05602194

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.